Cellectar Biosciences, Inc.
Cellectar Biosciences, Inc.
Your view on CLRB
Overview
What the company does, where it operates, and who runs it.
About Cellectar Biosciences, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- James V. Caruso
- Headquarters
- 100 Campus Drive, Florham Park, NJ, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- James V. Caruso
- Headquarters
- 100 Campus Drive, Florham Park, NJ, US
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer.
Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study in patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies; Phase 2B clinical study in r/r multiple myeloma (MM) patients; and Phase I study for various pediatric cancers, r/r head and neck cancers, and R/R MM.
The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative PDC programs with Avicenna Oncology GMBH to develop CLR 2000 Series; Orano Med to develop CLR 12120 Series; IntoCell Inc; and LegoChemBio.
The company was founded in 2002 and is headquartered in Florham Park, New Jersey.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Cellectar Biosciences, Inc., and the rating behind it. CLRB last traded at $2.31; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Cellectar Biosciences, Inc.. Starting points for Cellectar Biosciences, Inc.: EPS -$1.83, beta 0.56 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Cellectar Biosciences, Inc.. Cellectar Biosciences, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Cellectar Biosciences, Inc.. Trailing twelve-month EPS for Cellectar Biosciences, Inc. stands at -$1.83. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Cellectar Biosciences, Inc.. Cellectar Biosciences, Inc. has reported as a listed company since 2005. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Cellectar Biosciences, Inc. valued side by side against its closest peers. Cellectar Biosciences, Inc. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Cellectar Biosciences, Inc., and how their positions are changing. At a $18.5M market value, institutional positions materially move Cellectar Biosciences, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Cellectar Biosciences, Inc. executives and directors. Shares of Cellectar Biosciences, Inc. have traded between $2.71 and $50.70 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Cellectar Biosciences, Inc.. Cellectar Biosciences, Inc. is a $18.5M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Cellectar Biosciences, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Cellectar Biosciences, Inc.. Coverage tracks Cellectar Biosciences, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.